MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics today announced the completion of enrollment in the 1,320-patient AEGIS II (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trial, which is evaluating the diagnostic ability of the BronchoGen™ genomic test used in conjunction with bronchoscopy to detect early signs of lung cancer compared to the ability of bronchoscopy alone. BronchoGen is Allegro Diagnostics’ lead genomic test, and it is built upon the Company’s molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. Data from the AEGIS II study are expected in mid-2013.
